Collagen type VII alpha 1 chain (COL7A1) gene locus (COL7A1)

The genomic COL7A1 mutant locus refers to the specific chromosomal site of the Collagen Type VII Alpha 1 chain gene that harbors pathogenic mutations. This gene encodes the alpha chain of type VII collagen, which is the primary component of anchoring fibrils that secure the epidermis to the underlying dermis (UniProt P12133). Mutations in this locus lead to Dystrophic Epidermolysis Bullosa (DEB), a severe genetic skin fragility disorder characterized by chronic blistering, scarring, and a high risk of aggressive squamous cell carcinoma (NIH GARD). Therapeutic strategies targeting this locus include gene replacement therapy, such as the FDA-approved Beremagene geperpavec, which delivers functional COL7A1 cDNA to skin cells using a viral vector (FDA 2023). Experimental approaches also include CRISPR/Cas9-mediated gene editing and base editing designed to permanently correct mutations directly at the genomic level, as well as antisense oligonucleotides that induce exon skipping to restore a partially functional protein (Nature Communications, 2022). Successful intervention at this locus aims to restore the production of functional type VII collagen and the formation of stable anchoring fibrils, thereby improving skin integrity and patient quality of life.

Other names

COL7A1Collagen VII geneEBD1EBD2EBR1LCAMB

Gene replacement therapy (delivery of functional COL7A1 cDNA), Gene editing (CRISPR/Cas9 or base editing to correct genomic mutations), Exon skipping (antisense oligonucleotides to bypass mutated exons), and Protein replacement therapy.